Literature DB >> 25101344

Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis.

William J Eastman1, Steven Malahias, John Delconte, Dana DiBenedetti.   

Abstract

There is limited information available regarding patient preferences and attributes of topical product formulations for specific dermatologic conditions. This study focused on product attributes that were most desirable for 3 dermatologic conditions: acne, atopic dermatitis (AD), and plaque psoriasis (PP). Six focus groups were conducted with participants self-reporting 1 of these conditions and use of 2 or more topical treatments. Discussion focused on symptoms, treatments tried, and vehicle attributes. Fifty-four subjects participated: acne, n=19; AD, n=18; and PP, n=17. The most commonly reported prescription medication vehicles were creams and ointments, followed by lotions, gels, and foams. Itching and redness were the only symptoms spontaneously reported across all 6 focus groups. The attributes considered most important across all conditions included: moisturizing, absorbs/disappears/dries quickly, available in various formulations, does not bleach or stain skin/hair/clothing, is not greasy or oily, is not sticky or tacky, is long lasting/long acting, is fragrance or odor free, is easy to apply/simple to use, and can use all the time. Preferences attributable to acne included: easy to dispense/dispenses right amount, nondrying, product goes on/spreads smoothly, container is not easily broken/does not leak, and creamy. Preferences attributable to AD included: not noticeable to others/conceals area, good consistency, and cooling. Patient preference for product vehicle is relevant to adherence as compliance is a major factor for high rates of failure for dermatologic treatments.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25101344

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  12 in total

1.  Patients' view of the differences in topical creams for radiation dermatitis prevention. A pilot study of cosmetic properties.

Authors:  Sebastia Sabater; Rafael Leon; Cesar Esteban; Jose Luis Añon; Meritxell Arenas
Journal:  Rep Pract Oncol Radiother       Date:  2019-06-06

2.  Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam is Effective, Independent of Body Mass Index and the Extent and Severity of Psoriasis.

Authors:  Linda Stein Gold; John Villumsen; Monika Rosen
Journal:  Dermatol Ther (Heidelb)       Date:  2016-10-06

3.  Patients with psoriasis have different preferences for topical therapy, highlighting the importance of individualized treatment approaches: randomized phase IIIb PSO-INSIGHTFUL study.

Authors:  C-H Hong; K A Papp; K W Lophaven; P Skallerup; S Philipp
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-09-14       Impact factor: 6.166

4.  Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study.

Authors:  C Paul; L Stein Gold; F Cambazard; R E Kalb; D Lowson; B Bang; C E M Griffiths
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-08-17       Impact factor: 6.166

5.  Gaps and recommendations for clinical management of truncal acne from the Personalising Acne: Consensus of Experts panel.

Authors:  Jerry Tan; Andrew Alexis; Hilary Baldwin; Stefan Beissert; Vincenzo Bettoli; James Del Rosso; Brigitte Dréno; Linda Stein Gold; Julie Harper; Charles Lynde; Diane Thiboutot; Jonathan Weiss; Alison M Layton
Journal:  JAAD Int       Date:  2021-08-17

6.  Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict.

Authors:  Lars Iversen; Henny B Jakobsen
Journal:  Dermatol Ther (Heidelb)       Date:  2016-04-28

7.  Mycophenolic Acid for Topical Immunosuppression in Vascularized Composite Allotransplantation: Optimizing Formulation and Preliminary Evaluation of Bioavailability and Pharmacokinetics.

Authors:  Firuz G Feturi; Matthias Weinstock; Wenchen Zhao; Wei Zhang; Jonas T Schnider; Vasil E Erbas; Sinan Oksuz; Jan A Plock; Lisa Rohan; Alexander M Spiess; Lydia M Ferreira; Mario G Solari; Raman Venkataramanan; Vijay S Gorantla
Journal:  Front Surg       Date:  2018-05-09

8.  Psoriasis patients' experiences concerning medical adherence to treatment with topical corticosteroids.

Authors:  Mathias Tiedemann Svendsen; Klaus Ejner Andersen; Flemming Andersen; Jakob Hansen; Anton Pottegård; Helle Johannessen
Journal:  Psoriasis (Auckl)       Date:  2016-08-23

Review 9.  Patient Centric Pharmaceutical Drug Product Design-The Impact on Medication Adherence.

Authors:  Enrica Menditto; Valentina Orlando; Giuseppe De Rosa; Paola Minghetti; Umberto Maria Musazzi; Caitriona Cahir; Marta Kurczewska-Michalak; Przemysław Kardas; Elísio Costa; José Manuel Sousa Lobo; Isabel F Almeida
Journal:  Pharmaceutics       Date:  2020-01-03       Impact factor: 6.321

Review 10.  Fixed-Combination Halobetasol Propionate and Tazarotene in the Treatment of Psoriasis: Narrative Review of Mechanisms of Action and Therapeutic Benefits.

Authors:  Mark G Lebwohl; Emil A Tanghetti; Linda Stein Gold; James Q Del Rosso; Nelly K Gilyadov; Abby Jacobson
Journal:  Dermatol Ther (Heidelb)       Date:  2021-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.